1-3 of 3
Katrina S. Pedersen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy

Patrick M. Grierson, Rama Suresh, Benjamin Tan, Katrina S. Pedersen, Manik Amin, Haeseong Park, Nikolaos A. Trikalinos, Jingxia Liu, Nicholas Boice, Amberly Brown, Sapana Bansod, Andrea Wang-Gillam, Kian-Huat Lim
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4733–4739.
https://doi.org/10.1158/1078-0432.CCR-23-1405
Published: 01 December 2023
View article titled, A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy
Open the PDF for A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy in another window
Includes: Supplementary data
Journal Articles

Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors

Jonathan W. Goldman, Sarina A. Piha-Paul, Brendan Curti, Katrina S. Pedersen, Todd M. Bauer, Stefanie L. Groenland, Richard D. Carvajal, Vaishali Chhaya, Gray Kirby, Kelly McGlinchey, Scott A. Hammond, Katie Streicher, Danielle M. Townsley, Young Kwang Chae, Jens Voortman, Aurelien Marabelle, John Powderly
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3709–3719.
https://doi.org/10.1158/1078-0432.CCR-21-3016
Published: 01 September 2022
View article titled, Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors
Open the PDF for Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma

Katrina S. Pedersen, Nathan R. Foster, Michael J. Overman, Patrick M. Boland, Sunnie S. Kim, Kathryn A. Arrambide, Brandy L. Jaszewski, Tanios Bekaii-Saab, Rondell P. Graham, Jack Welch, Richard H. Wilson, Robert R. McWilliams
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (13): 3641–3648.
https://doi.org/10.1158/1078-0432.CCR-21-0159
Published: 01 July 2021
View article titled, ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma
Open the PDF for ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma in another window
Includes: Supplementary data